The initial excitement has since led to at least 90 monotherapy clinical trials on a wide range of human cancers with several generations of either natural or synthetic small molecule inhibitors that all bind to the N-terminal denosine triphosphate/Adenosine diphosphate binding site of Hsp90 proteins (see ClinicalTrials.gov). This evidence concerns the gene HSP90AA1 and cancer.